The Patent Finder

Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease

Biodesix, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 11/396,328, filed Mar 31, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,024,282Method for Reliable Classification of Samples in Clinical Diagnostics Using an Improved Method of Classification
In force
 · High confidence
Biodesix Inc.In force
High confidence
US 7,736,905Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease
In force
 · High confidence
Biodesix, Inc., a Delaware CorporationIn force
High confidence
US 9,152,758Method and system for determining whether a drug will be effective on a patient with a disease
In force
 · High confidence
Biodesix Inc.In force
High confidence
US 7,858,390Selection of Colorectal Cancer Patients for Treatment with Drugs Targeting Egfr Pathway
Lapsed Dec 28, 2022 on the fee record
Ended Dec 28, 2022 · Medium confidence
Biodesix Inc.Lapsed Dec 28, 2022 on the fee recordEnded Dec 28, 2022
Medium confidence
US 7,867,775Selection of Head and Neck Cancer Patients for Treatment with Drugs Targeting Egfr Pathway
Term ended
Term ended Mar 31, 2026 · High confidence
Biodesix Inc.Term endedTerm ended Mar 31, 2026
High confidence
US 7,879,620Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease
Term ended
Term ended Mar 31, 2026 · High confidence
Biodesix Inc.Term endedTerm ended Mar 31, 2026
High confidence
US 8,097,469Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease
Term ended
Term ended Mar 31, 2026 · High confidence
Biodesix Inc.Term endedTerm ended Mar 31, 2026
High confidence
US 8,119,417Monitoring Treatment of Head and Neck Cancer Patients with Drugs Egfr Pathway Using Mass Spectrometry of Patient Samples
Term ended
Ended no later than Mar 31, 2026 · Medium confidence
Biodesix Inc.Term endedEnded no later than Mar 31, 2026
Medium confidence
US 8,119,418Monitoring Treatment of Colorectal Cancer Patients with Drugs Targeting Egfr Pathway Using Mass Spectrometry of Patient Samples
Term ended
Ended no later than Mar 31, 2026 · Medium confidence
Biodesix Inc.Term endedEnded no later than Mar 31, 2026
Medium confidence
US 8,586,379Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
Term ended
Ended no later than Mar 31, 2026 · Medium confidence
Biodesix Inc.Term endedEnded no later than Mar 31, 2026
Medium confidence
4 more patents in this group · Pro
10 of 14 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 14, including 11 expired and 2 expiring within the 18 months from Nov 16, 2026.
Upgrade to Pro
3 of these are in force and held by Biodesix, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited